Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avapritinib versus regorafenib in advanced gastrointestinal stromal tumor after prior TKI therapy
2017-003497-14Phase 3Unknown
- Sponsor
- Blueprint Medicines
- Start
- Mar 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in gastrointestinal stromal tumor (GIST) comparing Avapritinib with Regorafenib (2 arms). Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
avapritinibregorafenib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on 2017-003497-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003497-14.